|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Peg-IFN combined with TDF may increase the virological response rate, biochemical response rate, and HBsAg loss rate in patients with CHB infection.
|
31114265 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
(Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients.
|
30715261 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-λ has recently been tested in clinical trials of chronic hepatitis B virus infection (CHB), with the advantage that side effects may be limited compared with IFN-α, as IFN-λ receptors are found only in epithelial cells.
|
30097535 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of these features, new therapeutic trials based upon a combination of PEG-IFN and third generation NUC such as entecavir and tenofovir, in both naïve and NUC-exposed patients, are ongoing to further increase the rates of HBsAg seroclearance, which remains the 'ideal end-point' in all HBeAg-negative CHB subjects.
|
23286860 |
2013 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic hepatitis B (CHB) patients with advanced fibrosis are often not considered for treatment with peginterferon (PEG-IFN) because IFN therapy may precipitate immunological flares, potentially inducing hepatic decompensation.
|
17604363 |
2007 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination with ETV and PEG-IFN could be an option for treatment of CHB patients especially in those with baseline HBsAg levels of less than 3.5 log U/ml.
|
29438098 |
2018 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared to the rs7574865 GT/TT genotype, the GG genotype (a risk factor of CHB and hepatitis B virus-related hepatocellular carcinoma) was significantly associated with a reduced SVR rate in both patients who received IFNα-2b therapy (21.1% versus 37.2%, P = 0.01) and those who received pegylated IFNα-2a therapy (18.0% versus 41.2%, P = 9.74 × 10(-5) ).
|
26704347 |
2016 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data from this study demonstrated for the first time that IP-10 polymorphism is independently associated with treatment response to PEG-IFN in patients with HBeAg-positive CHB.
|
26376789 |
2016 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even after stimulation by TLR agonists, no change was found in IFN-α production in CHB patients.
|
27658394 |
2016 |
|
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of IFN-α/βR-2 in monocytes can be used as a predictable parameter to evaluate the effect of IFN-α treatment in CHB patients.
|
21445562 |
2011 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extended treatment with PEG IFNα-2a with lamivudine or adefovir for 96 weeks is a promising strategy to achieve high rates of sustainable HBeAg and HBsAg seroconversion and HBV DNA suppression in patients with HBeAg-positive CHB.
|
23615131 |
2013 |
|
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, IFN-α boosted the expression of Mx2 and cytokine genes in γδT cells from CHB patients in vitro.
|
25774808 |
2015 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
HBsAg is a strong predictor of response to PEG-IFN in HBeAg-positive CHB.
|
23553752 |
2013 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, only a minority of chronic hepatitis B (CHB) patients generate a sustained response after treatment with recombinant IFNα.
|
27839836 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the limited efficacy is the main factor restricting the use of PEG-IFNα in CHB and therefore identifying the predictors of response is of great clinical importance.
|
24373089 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL28-B polymorphisms are related to different response in the treatment of CHB HBeAg-negative with PEG-IFN, and the E genotype is a novel negative predictive factor.
|
24316030 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to characterize the correlation between Peg-IFN-α antiviral effect and IFN-inducing signaling in CHB patients who switched to Peg-IFN from long time entecavir (ETV) treatment, we investigated the dynamic expression of interferon-stimulated genes (ISGs), including STAT1, MX, and a negative regulatory factor, suppressor of cytokine signaling 3(SOCS3), which negatively regulate IFN JAK-STAT signaling pathway by interacting with STAT1 and STAT2, in peripheral blood and paired liver samples, obtained from 54 CHB patients enrolled in a clinical trial, OSST study.
|
28988797 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, ss469415590 genotypes were not associated with response to PEG-IFN in Thai patients with HBeAg-positive and HBeAg-negative CHB.
|
26225703 |
2015 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the expression and function of TLR8 in peripheral blood mononuclear cells (PBMCs) of chronic hepatitis B (CHB) patients and its alteration during peg-IFN-α-2a therapy.
|
28236535 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the role of retinoic acid-inducible gene-I (RIG-I) in prediction of IFN-α curative effect of CHB patients.
|
29790851 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
On-treatment HBsAg decline during PEG-IFN therapy for HBeAg-positive CHB depends upon HBV genotype.
|
22267464 |
2012 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data have important implications for the treatment of CHB patients who fail to show an early response to Peg-IFNα-2a monotherapy.
|
28854883 |
2017 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that SNP rs4646536 in the CYP27B1 gene is a predictive factor of response to PEG-IFN therapy in Thai patients with CHB.
|
28291736 |
2017 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data support that SNP rs7574865 is associated with response to PEG-IFN therapy in Thai patients with CHB, regardless of baseline HBeAg status.
|
31421662 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicated that serum TCHO was associated with PEG-IFN-α therapeutic response in HBeAg-positive CHB patients which suggested that serum TCHO could be useful as an auxiliary clinical factor to predict poor efficacy of PEG-IFN-α therapy.
|
30520414 |
2019 |